$4.21 -0.22 (-5.06%)
Entero Therapeutics, Inc. Common Stock (ENTO)
Entero Therapeutics, Inc. (ENTO) is a biopharmaceutical company focused on developing neuromodulation therapies for gastrointestinal and metabolic diseases. The company leverages its proprietary EnteroMedics platform, including the vagus nerve modulation technology, to develop treatments aimed at improving conditions such as obesity and other gastrointestinal disorders.
Company News
Entero Therapeutics Appoints Richard Paolone as CEO
Entero Therapeutics, a clinical-stage biopharmaceutical company, has appointed Richard Paolone as the interim CEO. Paolone is a Toronto-based securities lawyer with extensive experience in corporate finance, securities law, and mergers and acquisitions.